Advertisement

Dyslipidemias

Chapter
  • 692 Downloads
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Dyslipidemias should be considered as being a result of primary and secondary causes.

Keywords

Statin Therapy Trans Fatty Acid Cholesteryl Ester Transfer Protein Familial Hypercholesterolemia Scandinavian Simvastatin Survival Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Area M, Vega GL, Grundy SM. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. JAMA 1994;271:453.CrossRefGoogle Scholar
  2. 2.
    Aro A, Kindinaal AFM, Salminen I, et al. Adipose tissue isomeric trans fatty acids and risk of myocardial infarction in nine countries: the EURAMIC study. Lancet 1995;345:273.PubMedCrossRefGoogle Scholar
  3. 3.
    Ascherio A, Rimm ENB, Stampfer MJ, et al. Dietary intake of marine o-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977.PubMedCrossRefGoogle Scholar
  4. 4.
    AVERT: Pitt B, Waters D, Brown WV, et al. for the atorvastatin versus revascularization treatment investigators: aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70–76.PubMedCrossRefGoogle Scholar
  5. 5.
    Birjmohun RS, Hutten BA, Kastelein JP, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:244–245.CrossRefGoogle Scholar
  6. 6.
    Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278–287.PubMedCrossRefGoogle Scholar
  7. 7.
    Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43.PubMedCrossRefGoogle Scholar
  8. 8.
    Bradford RH, Shear CL Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994;74:667.PubMedCrossRefGoogle Scholar
  9. 9.
    Brewer Jr HB. Increasing HDL cholesterol levels. N Eng J Med 2004;350:1491–1494.CrossRefGoogle Scholar
  10. 10.
    Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505–1515.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036–1043.PubMedCrossRefGoogle Scholar
  12. 12.
    Brown MS, Goldstein JL. A recept mediated parthway for cholesterol homeostasis. Science 1979;323:361.Google Scholar
  13. 13.
    Byington RP, Worthy J, Craven T. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the beta-blocker heart attack trial experience. Am J Cardiol 1990;65:1287.PubMedCrossRefGoogle Scholar
  14. 14.
    Calhoun DA, Oparil S. Hypertensive crisis since FDR-a partial victory. N Engl J Med 1995;332:1029.PubMedCrossRefGoogle Scholar
  15. 15.
    Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [PROVE IT-TIMI 22 trial]. N Engl J Med 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  16. 16.
    CCAIT Study Group-The Canadian Coronary Atherosclerosis Intervention Trial. Walters D, Higginson L, Gladstone, P, et al., For the CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959.Google Scholar
  17. 17.
    Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220.PubMedCrossRefGoogle Scholar
  18. 18.
    Davidson M, Ma P, Stein EA, et al. Comparison of effects on low density lipoprotein cholesterol and high density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypocholesterolemia. Am J Cardiol 2002;89:268–275.PubMedCrossRefGoogle Scholar
  19. 19.
    de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454.PubMedCrossRefGoogle Scholar
  20. 20.
    Deslypere JP. Clinical implications of the biopharmaceutical properties of the fluvastaiin. Am J Cardiol 1994;73:12D.PubMedCrossRefGoogle Scholar
  21. 21.
    Durrington P. Dyslipidaemia. Lancet 2003;362:717–731.PubMedCrossRefGoogle Scholar
  22. 22.
    Expert Panel on detection evaluation and treatment of high blood cholesterol in Adults: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486.Google Scholar
  23. 23.
    The 4S Investigators. Randomised trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383–1389.Google Scholar
  24. 24.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-Prevention trial with gemfi-brozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237.PubMedCrossRefGoogle Scholar
  25. 25.
    Gagne C, Caudet D, Bruckert E. Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–2475.PubMedCrossRefGoogle Scholar
  26. 26.
    Genest J, McNamara JR, Ordovas JM, et al. Lipoprolein cholesterol, apolipoprolein A–I and B and lipoprolein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792.PubMedCrossRefGoogle Scholar
  27. 27.
    Gharavi AG, Diamond JA, Smith DA, et al. Niacin-induced myopalhy. Am J Cardiol 1994;74:841.PubMedCrossRefGoogle Scholar
  28. 28.
    Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585–2590.PubMedCrossRefGoogle Scholar
  29. 29.
    Grundy SM. Atherosclerosis imaging and the future of lipid management. Circulation 2004;110:3509–3511.PubMedCrossRefGoogle Scholar
  30. 30.
    Grundy SM, Cleeman JI, Noel Bairey Merz C, et al. and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel in Guidelines. J Am Coll Cardiol 2004;44:720–732.PubMedCrossRefGoogle Scholar
  31. 31.
    Guallar E, Hennekens CH, Sacks FM, et al. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. J Am Coll Cardiol 1995;25:387.PubMedCrossRefGoogle Scholar
  32. 32.
    Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a Randomised placebo-controlled trial. Lancet 2002;360:7–22.CrossRefGoogle Scholar
  33. 33.
    Hu FB. The Mediterranean diet and mortality Olive oil and beyond. N Engl J Med 2003;348:2595–2596.PubMedCrossRefGoogle Scholar
  34. 34.
    Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995;76:54A.PubMedCrossRefGoogle Scholar
  35. 35.
    Jones PH, Davidson MH, Stein EA. Et al for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin, versus atorvastatin, simvastatin, and, pravastatin across doses. (STELLARTrial). Am J Cardiol 2003;93:152–160.CrossRefGoogle Scholar
  36. 36.
    Katan MB. Fish and heart disease. N Engl J Med 1995;332:1024.PubMedCrossRefGoogle Scholar
  37. 37.
    Keenan JM, Fontaine PL, Wenz JB, et al. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424.PubMedCrossRefGoogle Scholar
  38. 38.
    Knoops KTB, Lisette CP, deGroot GM, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European mean and women: the HALE Project. JAMA 2004;292:1433–1439.PubMedCrossRefGoogle Scholar
  39. 39.
    Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512.PubMedCrossRefGoogle Scholar
  40. 40.
    LIPID study group: prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.CrossRefGoogle Scholar
  41. 41.
    MAAS Investigators. Effect of simvastatin on coronary atherome: The Multi-Centre Anti Atheroma Study (MAAS). Lancet 1994;344:633.CrossRefGoogle Scholar
  42. 42.
    Mann GV. Metabolic consequences of dietary trans fatty acids. Lancet 1994;343:1268.PubMedCrossRefGoogle Scholar
  43. 43.
    MARS Study—The Monitored Atherosclerosis Regression Study, Lakenhorn DH, Azen SP, Kramsch DM, et al., and the MARS Research Group. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969.Google Scholar
  44. 44.
    MIRACL: Schwartz GG, Olsson AG, Ezcekowitz MD et al. effects of artovastatin on early recurrent ischemic events in acute coronary syndromes. A randomized controlled trial. JAMA 2001;285:1711–1718.PubMedCrossRefGoogle Scholar
  45. 45.
    Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestión of sustained-release nicotinic acid. Ann Intern Med 1989;111:253.PubMedGoogle Scholar
  46. 46.
    National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). 2002.Google Scholar
  47. 47.
    Nissen SE, for the REVERSAL Investigators. REVERSAL comparison of intensive versus moderate lipid lowering on the progression of coronary atherosclerosis measured by intravascular ultrasound: a randomized controlled trial. Circulation 2003;108:2723.Google Scholar
  48. 48.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of a recombinant Apo A-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003;290:2292–2300.PubMedCrossRefGoogle Scholar
  49. 49.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.PubMedCrossRefGoogle Scholar
  50. 50.
    Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044–1051.PubMedCrossRefGoogle Scholar
  51. 51.
    Oomen C M, Ocke MC, Fesksns EJM. Association between the transfer the acid intake and 10 year risk of coronary heart disease in the Zutphen elderly study: a prospective population base to study. Lancet 2001;357:746–751.PubMedCrossRefGoogle Scholar
  52. 52.
    Ridker PM, Cannon CP, Morrow D, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigator. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–28.PubMedCrossRefGoogle Scholar
  53. 53.
    Roberts TL, Wood DA, Riemersma RA, et al. Trans isomers of oleic and linoleic acids in adipose tissue and sudden cardiac death. Lancet 1995;345:278.PubMedCrossRefGoogle Scholar
  54. 54.
    Rosenson RS, Fraueheim WA. Safety of combined pravastatin-gemfiborzil therapy. Am J Cardiol 1994;74:499.PubMedCrossRefGoogle Scholar
  55. 55.
    Rubins HB, Robins ST, Collins D, et al. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol 1995;75:1196.PubMedCrossRefGoogle Scholar
  56. 56.
    Sacks FM for the Expert Group on HDL Cholesterol. The role of high-density lipoprotien (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139–143.PubMedCrossRefGoogle Scholar
  57. 57.
    Sacks FM, Pfeffer MA, Move LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.PubMedCrossRefGoogle Scholar
  58. 58.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344:1383–1389.CrossRefGoogle Scholar
  59. 59.
    Schmieder RE, Schobel HP. Is endothelial dysfunction reversible. Am J Cardiol 1995;76:117A.PubMedCrossRefGoogle Scholar
  60. 60.
    Schwartz GG, Oliver MF, Ezekowitz MD, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578–581.PubMedCrossRefGoogle Scholar
  61. 61.
    Shear CL, Franklin RA, Stinnett S, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992;85:1293.PubMedGoogle Scholar
  62. 62.
    Shepherd J, Cobbe SM, Ford I, et al. For the West of Scotland Coronary Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.PubMedCrossRefGoogle Scholar
  63. 63.
    Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high-risk patients (Indo-Mediterranean diet heart study): a randomized double-blind trial. Lancet 2002;360:1455–1461.PubMedCrossRefGoogle Scholar
  64. 64.
    Thompson PD, Clarkson P, Karas RH, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036–1043.CrossRefGoogle Scholar
  65. 65.
    Thompson PD, Clarkson P, Karas RH. Statin-Associated Myopathy. JAMA 2003;289:1681–1690.PubMedCrossRefGoogle Scholar
  66. 66.
    Topol EJ. Intensive statin therapy—a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562–1564.PubMedCrossRefGoogle Scholar
  67. 67.
    Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481.PubMedCrossRefGoogle Scholar
  68. 68.
    Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population N Engl J Med 2003;348:2599–2608.PubMedCrossRefGoogle Scholar
  69. 69.
    Wald NJ, Law N, Watt HC, et al. Apolipoproteins and ischemic heart disease implications for screening. Lancet 1995;343:75.CrossRefGoogle Scholar
  70. 70.
    Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocar dial infarction: the Framingham Study. Ann Intern Med 1991;115:687.PubMedGoogle Scholar
  71. 71.
    The Writing Group for the PEPI Trial. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations